Approval · Notice of Compliance 13347 · 2012

XYLAC: Notice of Compliance 13347

Issued June 5, 2012

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 13347
Date: June 5, 2012
Company: Pendopharm Division Of De Pharmascience Inc
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: Admin
Reason: Manufacturer name change
Therapeutic class: Antipsychotic

Products in this notice

Brand	DIN	Status today
XYLAC	02242868	Marketed
XYLAC	02230837	Dormant
XYLAC	02230838	Marketed
XYLAC	02230839	Marketed
XYLAC	02230840	Dormant
XYLAC	02239101	Cancelled Post Market

Medicinal ingredients

LOXAPINE SUCCINATE 2.5 MG per TAB
LOXAPINE SUCCINATE 5 MG per TAB
LOXAPINE SUCCINATE 10 MG per TAB
LOXAPINE SUCCINATE 25 MG per TAB
LOXAPINE SUCCINATE 50 MG per TAB
LOXAPINE HCL 25 MG per ML